Is Design Therapeutics Stock a Good Investment?
Design Therapeutics Investment Advice | DSGN |
- Examine Design Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Design Therapeutics' leadership team and their track record. Good management can help Design Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Design Therapeutics' business and its evolving consumer preferences.
- Compare Design Therapeutics' performance and market position to its competitors. Analyze how Design Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Design Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Design Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Design Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Design Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Design Therapeutics Stock
Researching Design Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 36.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.16. Some equities with similar Price to Book (P/B) outperform the market in the long run. Design Therapeutics recorded a loss per share of 0.88. The entity had not issued any dividends in recent years.
To determine if Design Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Design Therapeutics' research are outlined below:
| Design Therapeutics generated a negative expected return over the last 90 days | |
| Design Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (49.59 M) with loss before overhead, payroll, taxes, and interest of (44.35 M). | |
| Design Therapeutics currently holds about 359.38 M in cash with (43.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Design Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 814874 shares by William Arsani of Design Therapeutics at 4.25 subject to Rule 16b-3 |
Design Therapeutics Quarterly Cost Of Revenue |
|
Design Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Design Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Design Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Design Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Design Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-17 | 2024-12-31 | -0.2667 | -0.24 | 0.0267 | 10 | ||
2022-11-03 | 2022-09-30 | -0.29 | -0.32 | -0.03 | 10 | ||
2022-03-10 | 2021-12-31 | -0.23 | -0.2 | 0.03 | 13 | ||
2023-08-14 | 2023-06-30 | -0.4 | -0.36 | 0.04 | 10 | ||
2021-08-09 | 2021-06-30 | -0.18 | -0.14 | 0.04 | 22 | ||
2024-05-08 | 2024-03-31 | -0.26 | -0.2 | 0.06 | 23 | ||
2021-11-09 | 2021-09-30 | -0.14 | -0.21 | -0.07 | 50 | ||
2024-03-19 | 2023-12-31 | -0.31 | -0.21 | 0.1 | 32 |
Know Design Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Design Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Design Therapeutics backward and forwards among themselves. Design Therapeutics' institutional investor refers to the entity that pools money to purchase Design Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 761.6 K | State Street Corp | 2024-12-31 | 723.3 K | Mpm Oncology Impact Management Lp | 2024-12-31 | 559.5 K | D. E. Shaw & Co Lp | 2024-12-31 | 512.3 K | Ecor1 Capital, Llc | 2024-12-31 | 426.7 K | Northern Trust Corp | 2024-12-31 | 388.1 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 346.2 K | Goldman Sachs Group Inc | 2024-12-31 | 297.1 K | Charles Schwab Investment Management Inc | 2024-12-31 | 264.7 K | Sr One Capital Management, Lp | 2024-12-31 | 6.5 M | Logos Global Management Lp | 2024-12-31 | 4.2 M |
Design Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 279.84 M.Market Cap |
|
Design Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.26) | (0.24) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.20) | (0.19) |
Determining Design Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Design Therapeutics is a good buy. For example, gross profit margin measures Design Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Design Therapeutics' profitability and make more informed investment decisions.
Evaluate Design Therapeutics' management efficiency
Design Therapeutics has return on total asset (ROA) of (0.1439) % which means that it has lost $0.1439 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1908) %, meaning that it created substantial loss on money invested by shareholders. Design Therapeutics' management efficiency ratios could be used to measure how well Design Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of March 2025, Return On Tangible Assets is likely to drop to -0.21. In addition to that, Return On Capital Employed is likely to grow to -0.24. As of the 24th of March 2025, Asset Turnover is likely to grow to 0.000007, while Total Assets are likely to drop about 240.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.28 | 3.05 | |
| Tangible Book Value Per Share | 4.28 | 3.05 | |
| Enterprise Value Over EBITDA | (5.26) | (5.52) | |
| Price Book Value Ratio | 1.44 | 1.51 | |
| Enterprise Value Multiple | (5.26) | (5.52) | |
| Price Fair Value | 1.44 | 1.51 | |
| Enterprise Value | 328.1 M | 369.3 M |
At Design Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 1.776 |
Basic technical analysis of Design Stock
As of the 24th of March, Design Therapeutics shows the Variance of 31.53, mean deviation of 4.1, and Standard Deviation of 5.61. Design Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Design Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Design Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Design Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Design Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Design Therapeutics' Outstanding Corporate Bonds
Design Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Design Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Design bonds can be classified according to their maturity, which is the date when Design Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Design Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Design Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 4.1 | |||
| Coefficient Of Variation | (2,626) | |||
| Standard Deviation | 5.61 | |||
| Variance | 31.53 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | 0.0032 | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 24.91 | |||
| Value At Risk | (9.07) | |||
| Potential Upside | 8.72 | |||
| Skewness | 0.3179 | |||
| Kurtosis | 1.25 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 4.1 | |||
| Coefficient Of Variation | (2,626) | |||
| Standard Deviation | 5.61 | |||
| Variance | 31.53 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | 0.0032 | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 24.91 | |||
| Value At Risk | (9.07) | |||
| Potential Upside | 8.72 | |||
| Skewness | 0.3179 | |||
| Kurtosis | 1.25 |
Consider Design Therapeutics' intraday indicators
Design Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Design Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 1301.33 | |||
| Daily Balance Of Power | 1.866667 | |||
| Rate Of Daily Change | 1.06 | |||
| Day Median Price | 4.87 | |||
| Day Typical Price | 4.89 | |||
| Price Action Indicator | 0.2 | |||
| Period Momentum Indicator | 0.28 |
Design Therapeutics Corporate Filings
8K | 10th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 7th of February 2025 Other Reports | ViewVerify | |
F4 | 6th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 13th of August 2024 An amendment to the original Schedule 13D filing | ViewVerify |
Design Stock media impact
Far too much social signal, news, headlines, and media speculation about Design Therapeutics that are available to investors today. That information is available publicly through Design media outlets and privately through word of mouth or via Design internal channels. However, regardless of the origin, that massive amount of Design data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Design Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Design Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Design Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Design Therapeutics alpha.
Design Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Design Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Design Therapeutics Corporate Management
| Aseem Ansari | CoFounder Advisor | Profile | |
| Sean Jeffries | Chief Officer | Profile | |
| Elizabeth Gordon | Senior Affairs | Profile | |
| Mustapha Parekh | General Counsel | Profile | |
| Joo MD | CEO Pres | Profile | |
| MD FACC | Consulting Officer | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Design Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.